# Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453

> **NCT02845037** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 80 (actual)

## Conditions studied

- Hypertension
- Chronic Heart Failure

## Interventions

- **DRUG:** BIA 5-453
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02845037
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02845037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02845037, "Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02845037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*